InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Secret_Agent_Man who started this subject	10/11/2001 1:17:16 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 508

Did I get it right today that they are adding 150 to 175 new IPF patients each month on Actimmune? On Infergen and HCV. If that is not good enough, (it is) the P IV for Infergen shows it is superior to Intron A (each in combo with ribavirin) in treating HCV. [At 48 weeks 77% response to Infergen vs. 50% for Intron A and at 72 weeks after discontinuing treatment at 48, Infergen shows 44% sustained viral clearance vs. 31% for Intron A.] This is where an infusion study of Infergen could give us a preliminary idea whether PEG Infergen will continue to outperform PEG Intron A. Rather impressive. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next